var data={"title":"Tinidazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tinidazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7057?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tinidazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tinidazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=tinidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tinidazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708927\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Carcinogenic:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the 2 drugs are structurally related and have similar biologic effects. Reserve its use only for the conditions for which it is indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228029\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tindamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228048\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Amebicide;</li>\n      <li>\n        Antibiotic, Miscellaneous;</li>\n      <li>\n        Antiprotozoal, Nitroimidazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228033\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebiasis, intestinal:</b> Oral: 2 g once daily for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebiasis, liver abscess:</b> Oral: 2 g once daily for 3 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis:</b> Oral: 2 g once daily for 2 days or 1 g once daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis, recurrent (off-label dose):</b> Oral: 500 mg twice daily for 7 days followed by intravaginal therapy with boric acid, followed by intravaginal metronidazole suppressive therapy (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Giardiasis:</b> Oral: 2 g as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i></b>\n      <b> eradication (off-label use): </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concomitant regimen: </i>500 mg twice daily in combination with clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, and a standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sequential regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, tinidazole 500 mg twice daily, and a standard-dose proton pump inhibitor daily for 5 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hybrid regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, tinidazole 500 mg twice daily, and a standard-dose proton pump inhibitor twice daily for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault (off-label use):</b> Oral: 2 g as a single dose in combination with azithromycin plus ceftriaxone (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis:</b> Oral: 2 g as a single dose; sexual partners should be treated at the same time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis, persistent or recurrent (ie, treatment failure of nitroimidazole [eg, metronidazole]) (index case; treatment of sex partner; off-label dose):</b> Oral: 2 g once daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urethritis, nongonococcal (recurrent or persistent urethritis in men who have sex with women and who live in regions where <i>T. vaginalis</i> is prevalent; off-label use):</b> Oral: 2 g as a single dose. <b>Note:</b> Compliance with initial regimen and lack of reexposure to an untreated sex partner should be excluded prior to use (CDC [Workowski 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228042\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tinidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tinidazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebiasis, intestinal:</b> Oral: Children &gt;3 years and Adolescents: 50 mg/kg/day for 3 days (maximum dose: 2 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebiasis, liver abscess:</b> Oral: Children &gt;3 years and Adolescents: 50 mg/kg/day for 3 to 5 days (maximum dose: 2 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Giardiasis:</b> Oral: Children &gt;3 years and Adolescents: 50 mg/kg as a single dose (maximum dose: 2 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault (off-label use):</b> Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062235\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228034\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: An additional dose equal to <sup>1</sup>/<sub>2</sub> the  usual dose, should be administered at the end of hemodialysis if tinidazole is administered prior to hemodialysis on a dialysis days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228035\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228005\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tindamax: 250 mg [DSC], 500 mg [scored; contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227992\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228007\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228006\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebiasis</b>: Treatment of intestinal amebiasis and amebic liver abscess caused by <i>Entamoeba histolytica</i> in adults and pediatric patients older than 3 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not indicated for the treatment of asymptomatic cyst passage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis</b>: Treatment of bacterial vaginosis (formerly referred to as <i>Haemophilus </i>vaginitis, <i>Gardnerella vaginitis</i>, nonspecific vaginitis, or anaerobic vaginosis) in nonpregnant women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Giardiasis</b>: Treatment of giardiasis caused by <i>Giardia duodenalis</i> (also termed <i>Giardia lamblia</i>) in adults and pediatric patients older than 3 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis</b>: Treatment of trichomoniasis caused by <i>T. vaginalis</i>; treat partners of infected patients simultaneously to prevent reinfection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46461004\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Helicobacter pylori eradication; Prophylaxis against sexually transmitted diseases following sexual assault; Urethritis, nongonococcal (persistent and recurrent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227996\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;2%), malaise (&le;2%), dizziness (&le;1%), headache (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Body odor (vaginal: &gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypermenorrhea (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (bitter taste, metallic taste: 4% to 6%), nausea (3% to 5%), anorexia (2% to 3%), decreased appetite (&gt;2%), flatulence (&gt;2%), dyspepsia (&le;2%), abdominal cramps (&le;2%), epigastric distress (&le;2%), vomiting (1% to 2%), constipation (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vulvovaginal candidiasis (5%), dysuria (&gt;2%), pelvic pain (&gt;2%), urine abnormality (&gt;2%), vulvovaginal disease (discomfort) (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Urinary tract infection (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (&gt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, burning sensation, drowsiness, insomnia, peripheral neuropathy (transient; includes numbness and paresthesia), seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased thirst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, oral candidiasis, salivation, stomatitis, tongue discoloration, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dark urine, vaginal discharge</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia (transient), neutropenia (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis (overgrowth)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Bronchospasm, coma, confusion, depression, dyspnea, erythema multiforme, hairy tongue, hypersensitivity reaction (acute, severe), pharyngitis, Stevens-Johnson syndrome, thrombocytopenia (reversible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228011\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tinidazole, nitroimidazole derivatives, or any component of the formulation; pregnancy (first trimester); breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227994\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic: <b>[US Boxed Warning]: Carcinogenicity has been observed with another nitroimidazole derivative (metronidazole) in animal studies;</b> <b>use should be reserved for approved indications only.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Seizures and peripheral neuropathy (eg, extremity numbness and paresthesia) have been reported with tinidazole and other nitroimidazole derivatives; discontinue treatment if abnormal neurologic signs or symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD), pseudomembranous colitis, and/or vaginal candidiasis. CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Use with caution in patients with current or a history of blood dyscrasias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with current or a history of hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228043\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227999\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10205&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Tinidazole may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: Tinidazole may enhance the adverse/toxic effect of Disulfiram. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228024\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected. Management: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228002\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228013\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer contraindicates use of tinidazole during the first trimester of pregnancy. Adverse events have been observed in some animal reproduction studies. Tinidazole crosses the human placenta and enters the fetal circulation. The safety of tinidazole for the treatment of bacterial vaginosis or trichomoniasis in pregnant women has not been well evaluated. Other agents are preferred for use during pregnancy (CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228014\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tinidazole is excreted into breast milk in concentrations similar to those in the maternal serum and can be detected for up to 72 hours after administration. Tinidazole is contraindicated in nursing mothers unless breast-feeding is interrupted during therapy and for 3 days after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228015\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer recommends that ethanol be avoided during treatment and for 3 days after therapy is complete.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227993\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">After diffusing into the organism, it is proposed that tinidazole causes cytotoxicity by damaging DNA and preventing further DNA synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228010\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~50 L; distributes to most body tissues and fluids; crosses the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 (primarily); undergoes oxidation, hydroxylation and conjugation; forms a metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 13.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1.6 hours (fasting, delayed ~2 hours when given with food)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~20% to 25%); feces (~12%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422283\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tindamax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $342.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tinidazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (40): $203.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $203.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F228016\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amibiol (CO);</li>\n      <li>Asgin (TW);</li>\n      <li>Astiba (ET);</li>\n      <li>Cachtin (ET);</li>\n      <li>Dyzole (NZ);</li>\n      <li>Estovit-T (MX);</li>\n      <li>Fasdol (EC);</li>\n      <li>Fasigin (IT, PL);</li>\n      <li>Fasigyn (AE, AR, AT, BE, BG, BH, BZ, CH, CL, CO, CR, EG, GR, GT, HN, IL, IN, JO, KW, LB, LU, MX, NI, NL, PA, PE, PK, PT, QA, RU, SA, SE, SG, SI, SV, TH, UY, VE, VN, ZA);</li>\n      <li>Fasigyne (FR);</li>\n      <li>Fazyzhyn (UA);</li>\n      <li>Induken (MX);</li>\n      <li>Jie Li (CN);</li>\n      <li>Protogyn (AE, BD, BH, JO, LB, QA, SA);</li>\n      <li>Protozole (ET);</li>\n      <li>Simplotan (AT);</li>\n      <li>Su (TW);</li>\n      <li>T-Zol (BD);</li>\n      <li>Tindol (MY);</li>\n      <li>Tiniba (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Tinidan (EC);</li>\n      <li>Tinidazine (KR);</li>\n      <li>Tinirem (ET, TR);</li>\n      <li>Tinizol (BD, CR, DO, GT, HN, NI, PA, RO, SV);</li>\n      <li>Tinoral (BR);</li>\n      <li>Tiprogyn (RO);</li>\n      <li>Tricolam (ES);</li>\n      <li>Tricor 500 (PY);</li>\n      <li>Trinigyn (BB, BM, BS, GY, JM, SR, TT);</li>\n      <li>Troxxil (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28071659\"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825. doi: 10.1111/j.1572-0241.2007.01393.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamp KC, Freeman CD, Klutman NE, &ldquo;Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials,&rdquo; <i>Clin Pharmacokinet</i>, 1999, 36(5):353-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-drug-information/abstract-text/10384859/pubmed\" target=\"_blank\" id=\"10384859\">10384859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li XQ, Bjorkman A, Andersson TB, et al, &ldquo;Identification of Human Cytochrome P(450)s that Metabolise Anti-Parasitic Drugs and Predictions of <i>in vivo</i> Drug Hepatic Clearance from <i>in vitro</i> Data,&rdquo; <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):429-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-drug-information/abstract-text/12920490/pubmed\" target=\"_blank\" id=\"12920490\">12920490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tindamax (tinidazole) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; August 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tinidazole-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10205 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708927\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F228029\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F228048\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F228033\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F228042\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062235\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F228034\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F228035\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F228005\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F227992\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F228007\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F228006\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F46461004\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F227996\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F228011\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227994\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F228043\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F227999\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F228024\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F228002\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F228013\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F228014\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F228015\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227993\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F228010\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422283\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F228016\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10205|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tinidazole-patient-drug-information\" class=\"drug drug_patient\">Tinidazole: Patient drug information</a></li><li><a href=\"topic.htm?path=tinidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Tinidazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}